I hold SNT and ATX. I'm new to SNT but have been holding ATX for years. ATX have a FAK (focal adhesion kinase) inhibitor which essentially blocks the protein that causes the tissue around some solid tumours like pancreatic cancer to become tough. By weakening that tissue the tumours can be better treated but exisiting cancer treatments. ATX is looking pretty undervalued and quite promising so far.
I'm here to learn about SNT but it sounds like their molecule is stopping the forming of that tissue from an earlier stage. Does that sound correct? Who are the experts here?
Syntara the science explained, page-12
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
